{"id":11797,"date":"2026-11-11T11:09:19","date_gmt":"2026-11-11T05:39:19","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/cohance-share-price-today-2026-11-11\/"},"modified":"2026-11-11T11:09:21","modified_gmt":"2026-11-11T05:39:21","slug":"cohance-share-price-today-2026-11-11","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/cohance-share-price-today-2026-11-11\/","title":{"rendered":"Cohance Lifesciences Share Price Today: Why COHANCE Is Rising 3.00% | 11 November 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div class=\"wt-article-v4\" data-witty-phase=\"live\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: COHANCE<\/strong> \u00b7 11 November 2026<\/p>\n<div class=\"wt-price-strip\">\n<div>\n<div>Price<\/div>\n<div>\u20b9456.95<\/div>\n<\/div>\n<div>\n<div>Change<\/div>\n<div>+3.00%<\/div>\n<\/div>\n<div>\n<div>High \/ Low<\/div>\n<div>\u20b9465.95 \/ \u20b9441.25<\/div>\n<\/div>\n<div>\n<div>Prev. Close<\/div>\n<div>\u20b9443.65<\/div>\n<\/div>\n<div>\n<div>Volume<\/div>\n<div>4.26 lakh<\/div>\n<\/div>\n<div>\n<div>Price as of<\/div>\n<div>11 November 2026 \u00b7 10:30 AM IST<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-takeaways\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Key Takeaways<\/div>\n<div class=\"wt-card-body\">\n<ul class=\"wt-list\">\n<li>Cohance Lifesciences Ltd. (COHANCE) shares advanced 3.00% today, trading near the upper end of a \u20b9441.25 to \u20b9465.95 intraday range after opening at \u20b9445.00.<\/li>\n<li>Cohance Lifesciences announced that the United States Food and Drug Administration issued the Establishment Inspection Report for its manufacturing facility located at Pashamylaram, Hyderabad. The regulatory agency classified the inspection outcome as Voluntary Action Indicated, effectively concluding the inspection process.<\/li>\n<li>Trading volume was 0.57 times the 20-day average daily volume.<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<h2>Why is Cohance Lifesciences share price rising on 11 November 2026?<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Cohance Lifesciences Ltd. (COHANCE) shares advanced 3.00% today, trading near the upper end of a \u20b9441.25 to \u20b9465.95 intraday range after opening at \u20b9445.00.<\/p>\n<p class=\"wt-copy\">The broader market exhibited positive momentum, with the benchmark Nifty gaining 1.23%, while the thematic Nifty Pharma sector index slipped 0.52%. Cohance outperformed both the broader market and its sector peers, building on a 5-day return of 3.77% and a prior session return of 2.33%, though it remains down 1.19% over the past two trading days.<\/p>\n<p class=\"wt-copy\">Recent sentiment continues to draw context from the company&#x27;s fiscal second-quarter updates released earlier in November, where management reported a sequential revenue recovery of 12.90% quarter-on-quarter to \u20b94,767 million and an adjusted EBITDA margin improvement to 10% from 2% in the previous quarter. Additionally, the company announced that the USFDA issued an Establishment Inspection Report for its Pashamylaram manufacturing facility, classifying the outcome as Voluntary Action Indicated and formally concluding the inspection.<\/p>\n<p class=\"wt-copy\">4.26 lakh shares traded by 11 November 2026 \u00b7 10:30 AM IST. This compares with a 20-day average daily volume of 7.49 lakh shares (0.57 times). The five-day average daily volume was 5.17 lakh shares. Separately, the NSE report for 9 November 2026 showed 3.17 lakh shares delivered, representing 35.57% of that day\u2019s traded volume. The same report recorded 32,467 trades.<\/p>\n<\/div>\n<div class=\"wt-likely-reason\">\n<div class=\"wt-card\" data-card=\"research\" style=\"background:#f4f8fd;border:1px solid #cbd8ea;border-left:4px solid #466fa5;border-radius:10px\">\n<div class=\"wt-card-title\">Likely Reason<\/div>\n<div class=\"wt-card-body\"><strong>Stock-specific recovery following recent earnings traction and positive regulatory update<\/strong><\/p>\n<p class=\"wt-copy\">The 3.00% gain aligns with recent operational recovery reported in Q2 earnings and the successful closure of the USFDA inspection at the Pashamylaram plant, supported by recent positive return momentum.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div class=\"wt-grid wt-grid-news\">\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">USFDA Concludes Pashamylaram Inspection<\/div>\n<div class=\"wt-card-date\">7 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Cohance Lifesciences announced that the United States Food and Drug Administration issued the Establishment Inspection Report for its manufacturing facility located at Pashamylaram, Hyderabad. The regulatory agency classified the inspection outcome as Voluntary Action Indicated, effectively concluding the inspection process.<\/p>\n<p class=\"wt-copy\">Successful conclusion of the inspection clears regulatory overhang regarding this key manufacturing facility.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Q2 and H1 FY27 Financial Results<\/div>\n<div class=\"wt-card-date\">6 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">The company submitted its unaudited financial results for the quarter and half year ended September 30, 2026. Q2 operating revenue reached \u20b94,767 million, reflecting a 12.90% sequential recovery alongside an adjusted EBITDA of \u20b9458 million and an adjusted profit after tax of \u20b975 million.<\/p>\n<p class=\"wt-copy\">Provides baseline earnings data demonstrating sequential operational recovery from a weaker preceding quarter.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Investor Presentation and Business Outlook<\/div>\n<div class=\"wt-card-date\">7 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Cohance released its revised investor presentation detailing segment performance across Pharma CDMO, API+, and specialty chemicals, alongside strategic integration progress. Management indicated that the second half of fiscal 2027 is expected to be stronger than the first half, supported by improved order visibility and small molecule deliveries.<\/p>\n<p class=\"wt-copy\">Offers forward-looking visibility into management&#x27;s revenue and margin recovery expectations for the remainder of the fiscal year.<\/p>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Earnings \/ operating update<\/div>\n<div class=\"wt-card-date\">6 November 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SUVENPHARMSUSHEEL_06112026174827_Cohance_Outcome_BM_06112026_uploading.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"news\" style=\"background:#fff;border:1px solid #dce5eb;border-left:4px solid #2e7db2;border-radius:10px\">\n<div class=\"wt-card-title\">Management \/ board update<\/div>\n<div class=\"wt-card-date\">10 October 2026<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Appointment of Mr Abhimanyu Ojha as Chief Financial Officer of the company effective. October 12, 2026.<\/p>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/SUVENPHARMROHIT_09102026201959_Cohance_Outcome_BM_09102026.pdf\" rel=\"noopener\">Original source \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div class=\"wt-grid wt-grid-ownership\">\n<div class=\"wt-card\" data-card=\"ownership\" style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:4px solid #cc922c;border-radius:10px\">\n<div class=\"wt-card-title\">Shareholding<\/div>\n<div class=\"wt-card-date\">As of 30 September 2026<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-grid wt-grid-metrics\">\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Promoter holding<\/div>\n<div class=\"wt-value\">57.48%<\/div>\n<div class=\"wt-note\">57.49% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">FII\/FPI<\/div>\n<div class=\"wt-value\">7.71%<\/div>\n<div class=\"wt-note\">6.50% on 30 June 2026<\/div>\n<\/div>\n<div class=\"wt-metric\">\n<div class=\"wt-label\">Institutional holding<\/div>\n<div class=\"wt-value\">26.57%<\/div>\n<div class=\"wt-note\">26.59% on 30 June 2026<\/div>\n<\/div>\n<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739335_15102026071315_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"insider\" style=\"background:#edf5ff;border:1px solid #c9dbef;border-left:4px solid #4b7fb8;border-radius:10px\">\n<div class=\"wt-card-title\">Historical Insider Activity<\/div>\n<div class=\"wt-card-body\">\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Jusmiral Holdings Limited<\/strong><span class=\"wt-note\">Promoters<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>12.65 crore shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>9 May 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-insider-row\">\n<div class=\"wt-insider-person\"><strong>Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri<\/strong><span class=\"wt-note\">Director<\/span><\/div>\n<div><span class=\"wt-label\">Transaction<\/span><strong>Buy<\/strong><\/div>\n<div><span class=\"wt-label\">Quantity<\/span><strong>7.13 lakh shares<\/strong><\/div>\n<div><span class=\"wt-label\">Trade date<\/span><strong>9 May 2025<\/strong><\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">Source: NSE transaction disclosures. These are dated historical transactions.<\/div>\n<\/div>\n<\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">Mutual-fund ownership<\/div>\n<div class=\"wt-card-body\">\n<p class=\"wt-copy\">Mutual funds held 16.93% on 30 September 2026. This compares with 18.21% on 30 June 2026, a change of -1.28 percentage points.<\/p>\n<p class=\"wt-copy\">The filing reported 25 MF\/UTI holders.<\/p>\n<div class=\"wt-grid wt-grid-funds\">\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">SBI MNC FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.43 crore shares \u00b7 3.73%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">ICICI PRUDENTIAL HEALTHCARE FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.41 crore shares \u00b7 3.68%<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"funds\" style=\"background:#f7f9fc;border:1px solid #d5e0ea;border-left:4px solid #6a849c;border-radius:10px\">\n<div class=\"wt-card-title\">DSP FLEXI CAP FUND<\/div>\n<div class=\"wt-card-date\">30 September 2026<\/div>\n<div class=\"wt-card-body\">1.11 crore shares \u00b7 2.90%<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-note wt-source-note\">These are quarterly holdings, rather than purchases or sales on the article date.<\/div>\n<p><a class=\"wt-source\" href=\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739335_15102026071315_WEB.xml\" rel=\"noopener\">NSE shareholding filing \u2192<\/a><\/div>\n<\/div>\n<h2>Historical Bulk \/ Block Deals<\/h2>\n<div class=\"wt-grid wt-grid-cards\">\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">JASUB PROPERTY HOLDINGS LLP<\/div>\n<div class=\"wt-card-date\">9 November 2026<\/div>\n<div class=\"wt-card-body\">Buy \u00b7 30.00 lakh shares \u00b7 \u20b9430.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<div class=\"wt-card\" data-card=\"deals\" style=\"background:#fff8f2;border:1px solid #ead4c0;border-left:4px solid #b17640;border-radius:10px\">\n<div class=\"wt-card-title\">JASTI FAMILY TRUST<\/div>\n<div class=\"wt-card-date\">9 November 2026<\/div>\n<div class=\"wt-card-body\">Sell \u00b7 30.00 lakh shares \u00b7 \u20b9430.00<\/p>\n<div class=\"wt-note wt-source-note\">NSE-reported large-deal disclosure<\/div>\n<\/div>\n<\/div>\n<\/div>\n<h2>What to Watch Next<\/h2>\n<ul class=\"wt-list\">\n<li>Execution of stronger H2 order book and small molecule deliveries<\/li>\n<li>Progress on integration of Sapala and One Cohance platform initiatives<\/li>\n<li>Further developments regarding capital allocation and planned capex investments<\/li>\n<li>Sustained delivery volume participation above the 20-day average<\/li>\n<\/ul>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/cohance-share-price-today-2026-10-30\/\">Cohance Lifesciences Share Price Falls 8.10% Intraday, Closes 7.70% Lower | 30 October 2026 \u2014 30 October 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/cohance\/\">More Cohance Lifesciences news and dated analysis \u2192<\/a><\/p>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<div class=\"wt-faq\">\n<h3>What is the latest Cohance Lifesciences company news?<\/h3>\n<p class=\"wt-copy\">Cohance Lifesciences announced that the United States Food and Drug Administration issued the Establishment Inspection Report for its manufacturing facility located at Pashamylaram, Hyderabad. The regulatory agency classified the inspection outcome as Voluntary Action Indicated, effectively concluding the inspection process.<\/p>\n<h3>How strong was Cohance Lifesciences\u2019s trading volume?<\/h3>\n<p class=\"wt-copy\">4.26 lakh shares traded, 0.57 times the 20-day average daily volume. The price and volume data are dated 11 November 2026 \u00b7 10:30 AM IST.<\/p>\n<h3>Do the mutual-fund figures show buying today?<\/h3>\n<p class=\"wt-copy\">They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.<\/p>\n<\/div>\n<p><strong>Research &amp; analysis:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><br \/><strong>Reviewed by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">Mohanish Sanghavi \u2014 SEBI Registered Research Analyst<\/a><\/p>\n<p>Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.<\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@graph\": [{\"@type\": \"WebSite\", \"@id\": \"https:\/\/www.wittytrades.com\/#website\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"name\": \"WittyTrades\", \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"inLanguage\": \"en-IN\"}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#organization\", \"name\": \"WittyTrades\", \"alternateName\": \"Witty Networks\", \"url\": \"https:\/\/www.wittytrades.com\/\", \"telephone\": \"+91-22-48972020\", \"identifier\": [{\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}, {\"@type\": \"PropertyValue\", \"propertyID\": \"BSE Research Analyst Code\", \"value\": \"5430\"}]}, {\"@type\": \"Organization\", \"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"parentOrganization\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}}, {\"@type\": \"Person\", \"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\", \"name\": \"Mohanish Sanghavi\", \"jobTitle\": \"SEBI Registered Research Analyst\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\", \"worksFor\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"SEBI Research Analyst Registration\", \"value\": \"INH000008172\"}}, {\"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/cohance-share-price-today-2026-11-11\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/cohance-share-price-today-2026-11-11\/\"}, \"headline\": \"Cohance Lifesciences Share Price Today: Why COHANCE Is Rising 3.00% | 11 November 2026\", \"description\": \"Cohance Lifesciences share price rose 3.00% to \u20b9456.95 today. See why COHANCE is rising, volume context, company developments and what to watch next.\", \"datePublished\": \"2026-11-11T11:09:09.948451+05:30\", \"dateModified\": \"2026-11-11T11:09:09.948451+05:30\", \"author\": {\"@id\": \"https:\/\/www.wittytrades.com\/#research-desk\"}, \"reviewedBy\": {\"@id\": \"https:\/\/www.wittytrades.com\/About_Us.html#mohanish-sanghavi\"}, \"publisher\": {\"@id\": \"https:\/\/www.wittytrades.com\/#organization\"}, \"isPartOf\": {\"@id\": \"https:\/\/www.wittytrades.com\/#website\"}, \"about\": {\"@type\": \"Thing\", \"name\": \"Cohance Lifesciences\", \"identifier\": {\"@type\": \"PropertyValue\", \"propertyID\": \"NSE Symbol\", \"value\": \"COHANCE\"}}, \"inLanguage\": \"en-IN\", \"isAccessibleForFree\": true, \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/11\/cohance-company-news-2026-11-11.jpg\"]}]}<\/script><!-- wt-article-record:{\"recent_news\":[{\"summary\":\"Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.\",\"category\":\"Outcome of Board Meeting\",\"date\":\"06-Nov-2026 17:48:45\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUVENPHARMSUSHEEL_06112026174827_Cohance_Outcome_BM_06112026_uploading.pdf\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Cohance Lifesciences Stock Jumps Over 2% Despite Poor Q1 Earnings; Here's Why.\",\"category\":\"Business media\",\"published\":\"2026-08-06T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":3},{\"summary\":\"Cohance Lifesciences' 'Weakest Quarter' Prompts Target Price Cut By ICICI Securities.\",\"category\":\"Business media\",\"published\":\"2026-08-06T07:00:00+00:00\",\"source\":\"Business media\",\"headline\":\"Earnings \/ operating update\",\"impact\":\"Earnings updates are directly relevant to valuation. Revenue growth, margins, profit growth and management guidance are the key items to compare with expectations.\",\"importance_score\":5,\"completeness_score\":4},{\"summary\":\"Appointment of Mr Abhimanyu Ojha as Chief Financial Officer of the company effective. October 12, 2026.\",\"category\":\"Appointment\",\"date\":\"09-Oct-2026 20:21:16\",\"source\":\"NSE filing\",\"industry\":null,\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/SUVENPHARMROHIT_09102026201959_Cohance_Outcome_BM_09102026.pdf\",\"headline\":\"Management \/ board update\",\"impact\":\"Management and board changes can matter for execution, governance and continuity, although they do not automatically explain the day's share-price move.\",\"importance_score\":3,\"completeness_score\":4}],\"insider_activity\":[{\"person\":\"Jusmiral Holdings Limited\",\"category\":\"Promoters\",\"type\":\"Sell\",\"quantity\":\"34148000\",\"post_holding\":\"92390578\",\"date\":\"\",\"mode\":\"\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Jusmiral Holdings Limited\",\"category\":\"Promoters\",\"type\":\"Buy\",\"quantity\":\"126538578\",\"post_holding\":\"126538578\",\"date\":\"09-May-2025\",\"mode\":\"Scheme of Amalgamation\/Merger\/Demerger\/Arrangement\",\"source\":\"NSE PIT disclosure\"},{\"person\":\"Dr. Venkata Naga Kali Vara Prasada Raju Vetukuri\",\"category\":\"Director\",\"type\":\"Buy\",\"quantity\":\"713259\",\"post_holding\":\"713259\",\"date\":\"09-May-2025\",\"mode\":\"Scheme of Amalgamation\/Merger\/Demerger\/Arrangement\",\"source\":\"NSE PIT disclosure\"}],\"promoter_pledge\":{\"summary\":\"The promoter\/promoter-group disclosure states that the shares covered by the filing were free from encumbrance.\",\"events\":[{\"summary\":\"To The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai \u2013 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir\/Madam, Sub: Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011 (\u201cSEBI Takeover Regulations\u201d) Pursuant to Regulation 31(4) of the SEBI Takeover Regulations, we, Jusmiral Holding s Limited, promoter of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited), along with following persons acting in concert with Jusmiral Holdings Limited i.e., Berhyanda Limited (Promoter), Jusmiral Midco Limited, hereby declare that we have not made any encumbrance on the shares of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited), directly or indirectly, other than those already disclosed during the financial year 2025-26. This is for your information and record. Thanking you, Yours faithfully, For Jusmiral Holdings Limited _______________ Christodoulos Patsalides Director Copy to: The Audit Committee of Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Docusign Envelope ID: A7B227BB-8EEA-4110-8EB5-A5027\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"30-Jun-2026 15:58:01\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_12052026113906_49.pdf\",\"detail_level\":\"pdf_facts\"},{\"summary\":\"To The Manager Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Bandra (E), Mumbai \u2013 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir\/Madam, Sub: Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011 (\u201cSEBI Takeover Regulations\u201d) Pursuant to Regulation 31(4) of the SEBI Takeover Regulations, we, Berhyanda Limited, promoter of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited), along with following persons acting in concert with Berhyanda Limited i.e., Jusmiral Holdings Limited (Promoter), Berhyanda Midco Limited and Jusmiral Midco Limited, hereby declare that we have not made any encumbrance on the shares of Cohance Lifesciences Limited (Formerly, Suven Pharmaceuticals Limited ), directly or indirectly, other than those already disclosed during the financial year 2025-26. This is for your information and record. Thanking you, Yours faithfully, For Berhyanda Limited _______________ Christodoulos Patsalides Director Copy to: The Audit Committee of Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Docusign Envelope ID: A7B227BB-8EEA-411\",\"category\":\"Disclosure under SEBI Takeover Regulations\",\"date\":\"23-Jun-2026 20:45:57\",\"source\":\"NSE corporate filing\",\"attachment\":\"https:\/\/nsearchives.nseindia.com\/corporate\/team_sandeshc_12052026112842_Reg1.pdf\",\"detail_level\":\"pdf_facts\"}],\"source\":\"NSE corporate filing\"},\"shareholding_snapshot\":{\"promoter_pct\":57.48,\"public_pct\":42.52,\"fii_pct\":7.71,\"dii_pct\":18.86,\"mf_pct\":16.93,\"institutional_pct\":26.57,\"noninst_pct\":15.95,\"mf_scheme_count\":25,\"pledged_shares\":null,\"pledged_pct_of_promoter\":null,\"mf_holders\":[{\"name\":\"SBI MNC FUND\",\"shares\":14281118,\"pct\":3.73},{\"name\":\"ICICI PRUDENTIAL HEALTHCARE FUND\",\"shares\":14076711,\"pct\":3.68},{\"name\":\"DSP FLEXI CAP FUND\",\"shares\":11076502,\"pct\":2.9},{\"name\":\"HDFC TRUSTEE COMPANY LIMITED - HDFC TAX SAVERFUND\",\"shares\":8257896,\"pct\":2.16},{\"name\":\"INVESCO INDIA CONTRA FUND\",\"shares\":6157314,\"pct\":1.61}],\"period\":\"30-SEP-2026\",\"submission_date\":\"15-OCT-2026\",\"source\":\"NSE shareholding pattern XBRL\",\"source_url\":\"https:\/\/nsearchives.nseindia.com\/corporate\/xbrl\/SHP_1739335_15102026071315_WEB.xml\",\"previous_period\":\"30-JUN-2026\",\"previous_promoter_pct\":57.49,\"previous_fii_pct\":6.5,\"previous_dii_pct\":20.09,\"previous_mf_pct\":18.21,\"previous_institutional_pct\":26.59,\"previous_mf_scheme_count\":25,\"previous_pledged_pct_of_promoter\":null,\"previous_pledged_shares\":null},\"bulk_block_deals\":[{\"deal_type\":\"Block\",\"date\":\"09 Nov, 2026\",\"party\":\"JASUB PROPERTY HOLDINGS LLP\",\"side\":\"Buy\",\"quantity\":\"30,00,000\",\"price\":\"430\",\"value\":\"\u20b9129.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"},{\"deal_type\":\"Block\",\"date\":\"09 Nov, 2026\",\"party\":\"JASTI FAMILY TRUST\",\"side\":\"Sell\",\"quantity\":\"30,00,000\",\"price\":\"430\",\"value\":\"\u20b9129.00 Cr\",\"source\":\"NSE-reported large-deal disclosure\"}]} --><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cohance Lifesciences share price rose 3.00% to \u20b9456.95 today. See why COHANCE is rising, volume context, company developments and what to watch next.<\/p>\n","protected":false},"author":1,"featured_media":11796,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Cohance Lifesciences Share Price Today: Why COHANCE Is Rising 3.00% | 11 November 2026","_witty_meta_description":"Cohance Lifesciences share price rose 3.00% to \u20b9456.95 today. See why COHANCE is rising, volume context, company developments and what to watch next.","_witty_primary_phrase":"Cohance Lifesciences share price today","_witty_reason_label":"Stock-specific recovery following recent earnings traction and positive regulatory update","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[370],"class_list":["post-11797","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-cohance"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=11797"}],"version-history":[{"count":1,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11797\/revisions"}],"predecessor-version":[{"id":11798,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/11797\/revisions\/11798"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/11796"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=11797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=11797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=11797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}